Baseline characteristics of study patients
| Characteristic . | Placebo, N = 30 . | 6 mg senicapoc, N = 29 . | 10 mg senicapoc, N = 31 . | P† . |
|---|---|---|---|---|
| Sex, no. (%) | ||||
| Male | 15 (50) | 17 (59) | 13 (42) | .490 |
| Female | 15 (50) | 12 (41) | 18 (58) | — |
| Mean age, y (range) | 33.6 (19-55) | 37.2 (20-58) | 35.7 (21-60) | .375 |
| Mean weight, kg (range) | 69.2 (48-125) | 69.9 (49-109) | 66.9 (39-114) | .732 |
| Hospitalizations due to painful episodes in previous 12 mo*, no. (%) | ||||
| None | 6 (20) | 5 (17) | 12 (39) | .433 |
| 1 | 11 (37) | 5 (17) | 6 (19) | — |
| 2 to 3 | 7 (23) | 9 (31) | 6 (19) | — |
| More than 3 | 6 (20) | 9 (31) | 7 (23) | — |
| Characteristic . | Placebo, N = 30 . | 6 mg senicapoc, N = 29 . | 10 mg senicapoc, N = 31 . | P† . |
|---|---|---|---|---|
| Sex, no. (%) | ||||
| Male | 15 (50) | 17 (59) | 13 (42) | .490 |
| Female | 15 (50) | 12 (41) | 18 (58) | — |
| Mean age, y (range) | 33.6 (19-55) | 37.2 (20-58) | 35.7 (21-60) | .375 |
| Mean weight, kg (range) | 69.2 (48-125) | 69.9 (49-109) | 66.9 (39-114) | .732 |
| Hospitalizations due to painful episodes in previous 12 mo*, no. (%) | ||||
| None | 6 (20) | 5 (17) | 12 (39) | .433 |
| 1 | 11 (37) | 5 (17) | 6 (19) | — |
| 2 to 3 | 7 (23) | 9 (31) | 6 (19) | — |
| More than 3 | 6 (20) | 9 (31) | 7 (23) | — |